Details of QOL and PRO measurement included in trials
| QOL assessment . | Components . |
|---|---|
| EORTC QLQ-C30 | 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scale (fatigue, pain, and nausea/vomiting), 1 global health status/QOL scale, and 6 single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss, and financial difficulties) |
| FACT-Lym | 15 items for NHL-related symptoms and concerns |
| FACT-GP5 | Single question: if participant is bothered by side effects of treatment |
| EQ-5D-5L | General health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) |
| PGIC | 7-Point scale depicting rating of overall change since start of treatment |
| PGIS | 5-Point scale depicting rating of overall severity of disease symptoms over past 7 days |
| EORTC-NHL-LG20 | 20-Item questionnaire specifically for low-grade NHL, includes multi-item scales of symptom burden, physical condition, worries/fears, and emotional impact |
| FLymSI-18 | 18-Item questionnaire covers 4 subscales: physical symptoms, emotional symptoms, side effects, and functional well-being |
| PRO-CTCAE | PRO measurement system to assess symptomatic toxicity based on frequency, severity, interference, amount, and presence/absence |
| QOL assessment . | Components . |
|---|---|
| EORTC QLQ-C30 | 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scale (fatigue, pain, and nausea/vomiting), 1 global health status/QOL scale, and 6 single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss, and financial difficulties) |
| FACT-Lym | 15 items for NHL-related symptoms and concerns |
| FACT-GP5 | Single question: if participant is bothered by side effects of treatment |
| EQ-5D-5L | General health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) |
| PGIC | 7-Point scale depicting rating of overall change since start of treatment |
| PGIS | 5-Point scale depicting rating of overall severity of disease symptoms over past 7 days |
| EORTC-NHL-LG20 | 20-Item questionnaire specifically for low-grade NHL, includes multi-item scales of symptom burden, physical condition, worries/fears, and emotional impact |
| FLymSI-18 | 18-Item questionnaire covers 4 subscales: physical symptoms, emotional symptoms, side effects, and functional well-being |
| PRO-CTCAE | PRO measurement system to assess symptomatic toxicity based on frequency, severity, interference, amount, and presence/absence |
CTCAE, Common Terminology Criteria for Adverse Events; EORTC-NHL-LG20, European Organization for Research and Treatment of Cancer-Core QOL questionnaire low-grade NHL; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer-Core QOL questionnaire; EQ-5D-5L, EuroQOL 5-Dimension 5-Level; FACT-GP5, Functional Assessment of Cancer Therapy, General Population; FACT-Lym, Functional Assessment of Cancer Therapy, Lymphoma; FLymSI-18, Lymphoma Symptom Index-18; PGIC, Patient Global Impression of Change; PGIS, Patient Global Impression of Severity.